SiteOne Therapeutics, a Bozeman, Montana – based developer novel pain therapeutics and diagnostics to treat acute and chronic pain, closed a $15m series B round of financing.
The round was led by Amgen with participation from founding investors Next Frontier Capital, 2M Companies Inc., Mission Bay Capital, Sears Capital Management, Biobrit LLC, and Z Investments.
Founded with technology licensed from Stanford University and led by Stan Abel, President and Chief Executive Officer, SiteOne Therapeutics develops novel pain therapeutics and diagnostics to treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules.
The company intends to use the funds to accelerate the development of its Naᵥ1.7 therapeutic candidates in multiple potential applications for managing acute and chronic pain.